As most of you probably know, biotechnology company Serono, based in Geneva, Switzerland, agreed in October to pay $704 million to the United States federal government to settle charges that it illegally marketed its AIDS drug Serostim. According...
There has been a frenzy of activity in recent months with seemingly everyone involved in CME seeking to avoid negative publicity or to assure that their organizations are protected from official sanction from the Accreditation Council for CME...
CME providers agonize over eliminating the possible perception of bias in their activities due to pharmaceutical industry support, but are docs similarly concerned — and if so, are they concerned enough to pay their own way? For the first time...
I Recently Attended the American Heart Association annual meeting in Dallas. It was an impressive event — more than 27,000 attendees took over most of the city for five full days. The exhibit hall was inspirational, with pharmaceutical companies...
When I interviewed Marcia Jackson, PhD, American College of Cardiology, for the last installment in our women leaders series (see page 25), she told me she had just finished chemotherapy and radiation treatments for non-Hodgkin's lymphoma. I asked...
The horror story in the wake of Hurricane Katrina, played out in words and heart-wrenching photographs, is likely to be with us for months or, perhaps, years to come. It was truly incomprehensible to see hundreds of “refugees” on U.S. soil fleeing...
No Free Lunch was miffed when the American Academy of Family Physicians, Leawood, Kan., initially declined its request to exhibit at the AAFP Annual Meeting in San Francisco in September. No Free Lunch is a New York — based organization that...
Frustrated with finding funding for your continuing medical education activity? Tired of completing endless Web-based funding applications for pharmaceutical companies? You're not alone! To comply with Office of Inspector General rules...
Medical meeting planners in other countries are struggling with the very same dilemmas we face: How do we conduct CME in a fashion that best serves the physician community and patient well-being, and yet still remains of interest to commercial...